Blackrock’s Sending THIS Crypto Higher on Purpose

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

BTTX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 51.40%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Better Therapeutics Insider Trading History Chart

Better Therapeutics Share Price & Price History

^$0.00

+0.30 (1.20%)

As of 11/5/2024 01:00 AM ET

Days: 30 | 90 | 365

Blackrock’s Sending THIS Crypto Higher on Purpose

From Crypto 101 Media | Ad

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

YES, I WANT THE #1 CRYPTO NOW

Better Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/27/2023	Andrew J. Armanino	Director	Buy	274,010	$0.73	$200,027.30	728,368
7/27/2023	David P Perry	Chairman	Buy	1,233,045	$0.73	$900,122.85	13,030,393
7/27/2023	Frank Karbe	CEO	Buy	137,005	$0.73	$100,013.65	429,429
7/27/2023	Mark A Berman	Insider	Buy	54,802	$0.73	$40,005.46	388,191
5/16/2023	Elder Granger	Director	Buy	600	$0.87	$522.00	1,600
4/10/2023	Frank Karbe	Insider	Buy	242,424	$0.82	$198,787.68	292,424
4/10/2023	Geoffrey M Parker	Director	Buy	303,030	$0.82	$248,484.60	343,030
9/15/2022	Frank Karbe	Insider	Buy	50,000	$2.09	$104,500.00	50,000
9/12/2022	Mark Heinen	Insider	Buy	23,868	$1.94	$46,303.92	43,868
6/24/2022	Mark Heinen	Insider	Buy	2,281	$1.75	$3,991.75	2,281
6/13/2022	Geoffrey M Parker	Director	Buy	25,000	$1.45	$36,250.00	40,000
6/10/2022	Mark Heinen	Insider	Buy	5,000	$1.56	$7,800.00	20,000
3/31/2022	Kevin J. Appelbaum	CEO	Buy	2,500	$1.97	$4,925.00	6,250
3/31/2022	Mark Heinen	Insider	Buy	5,000	$1.98	$9,900.00	15,000
3/29/2022	Andrew J. Armanino	Director	Buy	40,000	$2.14	$85,600.00
12/21/2021	Risa J. Lavizzo-Mourey	Director	Buy	10,000	$4.60	$46,000.00
12/20/2021	Kevin J. Appelbaum	CEO	Buy	1,000	$4.60	$4,600.00
12/15/2021	Kevin J. Appelbaum	CEO	Buy	750	$4.71	$3,532.50
12/15/2021	Mark Heinen	Insider	Buy	2,333	$4.70	$10,965.10
12/13/2021	Andrew J. Armanino	Director	Buy	21,000	$5.48	$115,080.00
12/13/2021	Mark Heinen	Insider	Buy	500	$5.45	$2,725.00
12/10/2021	Kevin J. Appelbaum	CEO	Buy	1,000	$5.98	$5,980.00
12/3/2021	Elder Granger	Director	Buy	1,000	$6.66	$6,660.00
12/2/2021	Kevin J. Appelbaum	CEO	Buy	500	$6.84	$3,420.00
11/29/2021	Andrew J. Armanino	Director	Buy	17,000	$6.96	$118,320.00

The centerpiece of Trump’s crypto’s masterplan …

From Weiss Ratings | Ad

Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin conference in Nashville … Where he told an adoring crowd that the U.S. would become … “The crypto capital of the planet and the Bitcoin superpower of the world.”

Click here to find out more about what could be Trump and JD Vance’s favorite coin.

SEC Filings (Institutional Ownership Changes) for Better Therapeutics (NASDAQ:BTTX)

34.00% of Better Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Better Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/12/2024	MMCAP International Inc. SPC	356,270	$65K	0.0%	-77.5%	0.715%
11/14/2023	MMCAP International Inc. SPC	1,583,079	$0.58M	0.2%	N/A	3.340%
5/15/2023	Farallon Capital Management LLC	699,042	$0.51M	0.0%	-14.1%	2.931%
5/10/2022	Sectoral Asset Management Inc.	878,531	$1.74M	0.3%	-9.8%	3.721%
5/4/2022	Victory Capital Management Inc.	272,720	$0.54M	0.0%	N/A	1.155%

Data available starting January 2016

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

N/A

Average Volume

27,638 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.89

Who are the company insiders with the largest holdings of Better Therapeutics?: Better Therapeutics' top insider shareholders include:
David P Perry (Chairman)
Andrew J Armanino (Director)
Frank Karbe (CEO)
Mark A Berman (Insider)
Geoffrey M Parker (Director)
Frank Karbe (Insider)
Elder Granger (Director)
Learn More about top insider investors at Better Therapeutics.

From Porter & Company | Ad

The Pentagon has just made a critical $7.7 billion move. They're investing into one of the most controversial technologies the world has ever known… A technology I’m calling “The AI Keystone”, because without it, the AI industry is doomed.

Click here to watch his special investigative report into the controversial ‘AI Keystone’.